RIBOLIFE-B

Suzhou Ribo closed up 3.3% at HK$51.05 after an afternoon rally, reversing an early drop to HK$48.86 for a 7.2% intraday range. The move was driven by the first milestone achievement in the Madrigal collaboration for a MASH siRNA therapy, triggering milestone payments; additionally, the company filed a Phase II clinical trial application with the EMA for its anti-thrombotic siRNA RBD4059 and initiated a Phase III trial in China for the PCSK9 siRNA RBD7022, underscoring pipeline progress. Recent unveiling of the RiboPepSTAR™ platform for extra-hepatic delivery also supported sentiment. However, the stock remains 46.7% below its 52-week high of HK$95.8 and down 37.8% YTD, trading just above the 20-day MA of HK$49.755 but far below the 60-day MA of HK$57.657, with PE at -28.28x and PB at -83.72x reflecting ongoing losses.